Biomax Informatics AG Launches Version 4.0 of the BioRS Integration and Retrieval System

Apr 25, 2001, 01:00 ET from Biomax Informatics AG from ,InforMax, Inc.

    MARTINSRIED, Germany, April 25 /PRNewswire/ -- Biomax Informatics AG
 announces a new version of the BioRS Integration and Retrieval System,  which
 enables researchers instant access to multiple biological data sources,
 including in-house proprietary databases.  Although the BioRS system has
 always been able to integrate flat-file and relational databases, both
 internally represented in XML format, the new release further enhances
 performance and keeps the BioRS system at the cutting edge of innovative
 information exchange technology.  The new developments are part of the
 company's ongoing commitment to providing the most universal and user-friendly
 bioinformatics systems available.
     The BioRS system, first launched in 1998, is a high-speed, sophisticated
 search and retrieval system for biological information, such as DNA sequences.
 The speed and flexibility of the BioRS system greatly facilitates gene
 discovery projects, including genomics, proteomics and drug targeting and
 delivery.  The system enables researchers to quickly and efficiently retrieve
 all known biological data on a given topic, independent of the size of the
 database or the complexity of the query.  BioRS uses convenient web interfaces
 and standardizes data formats from different databases using eXtended Markup
 Language (XML) for quick, easy access to data, independent of the source
 format.  Both flat-file and relational databases, including proprietary
 databases, are easily integrated.
     The new release of the BioRS system further facilitates the use of
 relational databases.  With BioRS version 4.0, the format of an existing
 relational database can be copied making the creation and integration of new
 relational databases as easy as possible.
     Additionally, the new release will allow users to execute searches using
 phrases with all indexed fields, refining queries for more relevant search
 results.
     In response to customer requests, the query archive has been enhanced so
 that queries created by an individual user may be accessed by other users.
 This new feature allows information to be shared more efficiently by reducing
 redundant searches and ensuring that research goals are reached even more
 quickly.
     "Since our goal for the BioRS system has always been to make it the most
 efficient and effective database search and integration system, regardless of
 the type of databases used, we are pleased to bring these innovative features
 and their corresponding benefits to new and current customers," said Dr. Klaus
 Heumann, CEO of Biomax.  "As a provider of customized bioinformatics
 solutions, Biomax is in constant contact with customers and we make it our
 goal to constantly upgrade and fit our software to the requirements and
 demands of the user."
     In January 2001, Biomax granted InforMax of Rockville, Maryland exclusive,
 worldwide distribution rights to the BioRS Integration and Retrieval System.
 "InforMax has 500 customer organizations in Europe, including more than 150 in
 Germany alone," said Heumann.  "Integrating the BioRS system with InforMax's
 High-Throughput Research(TM) solution set will leverage our combined strength
 in Germany and create global synergies for both companies.  We are excited to
 be working with InforMax to deliver this industry-leading bioinformatics
 solution to the market and are confident that this alliance will significantly
 increase market share for BioRS worldwide."
 
     About Biomax
     Biomax Informatics AG (Martinsried, Germany), a leader in the development
 of customized bioinformatics solutions, was founded in 1997 as a spin-off of
 the GFS-MIPS academic research group of the German Research Center for
 Environment and Health (Neuherberg) and the Munich Information Center for
 Protein Sequences (Max Planck Institute for Biochemistry, Martinsried).
 Founded by Dr. D. Frishman, Dr. K. Heumann and Prof. Dr. H. W. Mewes, Biomax
 developed the well-known Pedant-Pro(TM) Sequence Analysis Suite, the BioRS
 Integration and Retrieval System, and other bioinformatics tools used in
 metabolic pathway, proteomics, and gene expression analyses. Additional
 information about Biomax can be found at the company's site on the World Wide
 Web at http://www.biomax.de .
 
     About InforMax
     InforMax (Nasdaq: INMX) is a leading global developer of bioinformatics
 software for High-Throughput Research(TM).  InforMax products are used by more
 than 1650 research organizations and more than 22,000 individual scientists
 worldwide (as of December 31, 2000) to understand and extract value from the
 massive amounts of data being generated by the Genomic Revolution. Among the
 Company's customers are 22 of the top 25 pharmaceutical companies. InforMax
 was founded in 1990 by Alex Titomirov, Ph.D.  Its mission is to speed the pace
 of medical progress by enabling High-Throughput Research(TM), a process for
 compressing the time it takes to discover and validate the biological targets
 most likely to result in breakthrough therapeutics, diagnostics or
 biomolecular interventions to cure or prevent disease. InforMax bioinformatics
 software solutions enable a full range of gene-to-genome analysis,
 interpretation and data mining. Its market-leading products include Vector
 NTI(R) Suite, the most widely used software suite for enhancing laboratory
 productivity, and GenoMax(TM) for integrated analysis of genomic and proteomic
 data. Additional information about InforMax can be found at the company's Web
 site at http://www.informaxinc.com .
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements, which involve a high degree of risk and
 uncertainty. Such statements are only predictions, and the actual events or
 results may differ materially from those projected in such forward-looking
 statements. Factors that could cause or contribute to differences include, but
 are not limited to, risks associated with the InforMax's technologies and the
 need to keep pace with rapid technological change, the Company's dependence
 for future revenues on its ability to increase sales of its enterprise
 platform and successfully establish the GenoMax brand, the Company's
 dependence on developing and maintaining strategic alliances, development and
 availability of competitive products or technologies, the possibility that the
 Company may not achieve or maintain profitability in the future, the
 likelihood that the Company's results may fluctuate from quarter to quarter,
 dependence on patents and the ability to defend the Company's intellectual
 property rights. These factors and others are more fully described in the
 Company's Registration Statement on Form S-1, as filed with the Securities and
 Exchange Commission. The Company specifically disclaims any intention or duty
 to update any forward-looking statements, and these statements represent the
 Company's current outlook only as of the date given.
 
     InforMax, the InforMax logo, and Vector NTI are registered trademarks and
 GenoMax and High-Throughput Research are trademarks of InforMax, Inc.
     Biomax, BioRS and Pedant-Pro are registered trademarks of Biomax
 Informatics AG.
     All other products or company names are used for identification purposes
 only, and may be the trademarks of their respective owners.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X58530394
 
 

SOURCE Biomax Informatics AG; InforMax, Inc.
    MARTINSRIED, Germany, April 25 /PRNewswire/ -- Biomax Informatics AG
 announces a new version of the BioRS Integration and Retrieval System,  which
 enables researchers instant access to multiple biological data sources,
 including in-house proprietary databases.  Although the BioRS system has
 always been able to integrate flat-file and relational databases, both
 internally represented in XML format, the new release further enhances
 performance and keeps the BioRS system at the cutting edge of innovative
 information exchange technology.  The new developments are part of the
 company's ongoing commitment to providing the most universal and user-friendly
 bioinformatics systems available.
     The BioRS system, first launched in 1998, is a high-speed, sophisticated
 search and retrieval system for biological information, such as DNA sequences.
 The speed and flexibility of the BioRS system greatly facilitates gene
 discovery projects, including genomics, proteomics and drug targeting and
 delivery.  The system enables researchers to quickly and efficiently retrieve
 all known biological data on a given topic, independent of the size of the
 database or the complexity of the query.  BioRS uses convenient web interfaces
 and standardizes data formats from different databases using eXtended Markup
 Language (XML) for quick, easy access to data, independent of the source
 format.  Both flat-file and relational databases, including proprietary
 databases, are easily integrated.
     The new release of the BioRS system further facilitates the use of
 relational databases.  With BioRS version 4.0, the format of an existing
 relational database can be copied making the creation and integration of new
 relational databases as easy as possible.
     Additionally, the new release will allow users to execute searches using
 phrases with all indexed fields, refining queries for more relevant search
 results.
     In response to customer requests, the query archive has been enhanced so
 that queries created by an individual user may be accessed by other users.
 This new feature allows information to be shared more efficiently by reducing
 redundant searches and ensuring that research goals are reached even more
 quickly.
     "Since our goal for the BioRS system has always been to make it the most
 efficient and effective database search and integration system, regardless of
 the type of databases used, we are pleased to bring these innovative features
 and their corresponding benefits to new and current customers," said Dr. Klaus
 Heumann, CEO of Biomax.  "As a provider of customized bioinformatics
 solutions, Biomax is in constant contact with customers and we make it our
 goal to constantly upgrade and fit our software to the requirements and
 demands of the user."
     In January 2001, Biomax granted InforMax of Rockville, Maryland exclusive,
 worldwide distribution rights to the BioRS Integration and Retrieval System.
 "InforMax has 500 customer organizations in Europe, including more than 150 in
 Germany alone," said Heumann.  "Integrating the BioRS system with InforMax's
 High-Throughput Research(TM) solution set will leverage our combined strength
 in Germany and create global synergies for both companies.  We are excited to
 be working with InforMax to deliver this industry-leading bioinformatics
 solution to the market and are confident that this alliance will significantly
 increase market share for BioRS worldwide."
 
     About Biomax
     Biomax Informatics AG (Martinsried, Germany), a leader in the development
 of customized bioinformatics solutions, was founded in 1997 as a spin-off of
 the GFS-MIPS academic research group of the German Research Center for
 Environment and Health (Neuherberg) and the Munich Information Center for
 Protein Sequences (Max Planck Institute for Biochemistry, Martinsried).
 Founded by Dr. D. Frishman, Dr. K. Heumann and Prof. Dr. H. W. Mewes, Biomax
 developed the well-known Pedant-Pro(TM) Sequence Analysis Suite, the BioRS
 Integration and Retrieval System, and other bioinformatics tools used in
 metabolic pathway, proteomics, and gene expression analyses. Additional
 information about Biomax can be found at the company's site on the World Wide
 Web at http://www.biomax.de .
 
     About InforMax
     InforMax (Nasdaq: INMX) is a leading global developer of bioinformatics
 software for High-Throughput Research(TM).  InforMax products are used by more
 than 1650 research organizations and more than 22,000 individual scientists
 worldwide (as of December 31, 2000) to understand and extract value from the
 massive amounts of data being generated by the Genomic Revolution. Among the
 Company's customers are 22 of the top 25 pharmaceutical companies. InforMax
 was founded in 1990 by Alex Titomirov, Ph.D.  Its mission is to speed the pace
 of medical progress by enabling High-Throughput Research(TM), a process for
 compressing the time it takes to discover and validate the biological targets
 most likely to result in breakthrough therapeutics, diagnostics or
 biomolecular interventions to cure or prevent disease. InforMax bioinformatics
 software solutions enable a full range of gene-to-genome analysis,
 interpretation and data mining. Its market-leading products include Vector
 NTI(R) Suite, the most widely used software suite for enhancing laboratory
 productivity, and GenoMax(TM) for integrated analysis of genomic and proteomic
 data. Additional information about InforMax can be found at the company's Web
 site at http://www.informaxinc.com .
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements, which involve a high degree of risk and
 uncertainty. Such statements are only predictions, and the actual events or
 results may differ materially from those projected in such forward-looking
 statements. Factors that could cause or contribute to differences include, but
 are not limited to, risks associated with the InforMax's technologies and the
 need to keep pace with rapid technological change, the Company's dependence
 for future revenues on its ability to increase sales of its enterprise
 platform and successfully establish the GenoMax brand, the Company's
 dependence on developing and maintaining strategic alliances, development and
 availability of competitive products or technologies, the possibility that the
 Company may not achieve or maintain profitability in the future, the
 likelihood that the Company's results may fluctuate from quarter to quarter,
 dependence on patents and the ability to defend the Company's intellectual
 property rights. These factors and others are more fully described in the
 Company's Registration Statement on Form S-1, as filed with the Securities and
 Exchange Commission. The Company specifically disclaims any intention or duty
 to update any forward-looking statements, and these statements represent the
 Company's current outlook only as of the date given.
 
     InforMax, the InforMax logo, and Vector NTI are registered trademarks and
 GenoMax and High-Throughput Research are trademarks of InforMax, Inc.
     Biomax, BioRS and Pedant-Pro are registered trademarks of Biomax
 Informatics AG.
     All other products or company names are used for identification purposes
 only, and may be the trademarks of their respective owners.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X58530394
 
 SOURCE  Biomax Informatics AG; InforMax, Inc.